Skip to content

A preclinical trial of daidzein supplement for postmenopausal osteoporosis

A preclinical trial of daidzein supplement for postmenopausal osteoporosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-11001222
Enrollment
Unknown
Registered
2011-03-14
Start date
2011-04-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postmenopausal Osteopenia or Osteoprosis

Interventions

Sponsors

Third Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
40 Years to 65 Years

Inclusion criteria

Inclusion criteria: 40~65 years, postmenopausal women who was natural menopause for more than 1 year and diagnosed as osteopenia or osteoporosis.

Exclusion criteria

Exclusion criteria: 1. women who were treated with parathyriod hormone, estrogen replacement therapy, or any medicine for osteoporosis currently; 2. undergone with parathyriod hormone or bisphosphonates last year, or received estrogen replacement therapy last half year; 3. suffer from fracture or any disease that influence bone metabolism except osteopenia or osteoporosis; 4. have estrogen dependent cancers or family history of such cancers; 5. suffer from gastrointestinal diseases, cardiovascular diseases, severe chronic diseases and liver or kidney disfunction, melignant tumors; 6. suffer from any acute or chronic infectious diseases or injury, or receive any surgery last month; 7. allergy to soy; 8. incompliance.

Design outcomes

Primary

MeasureTime frame
lumber BMD;

Countries

China

Contacts

Public ContactMantian Mi
mimt@sina.com+86 23 68752292

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026